Illumina
Supplies sequencing and array instruments, recurring consumables, informatics, and multiomics workflows.
Something off on this page? Send us feedback.
Profile
Sells sequencing and array instruments, consumables, informatics, and services to research and clinical customers worldwide. A broad installed base drives recurring flow-cell, reagent, library-preparation, and assay demand, while newer multiomics workflows extend the platform into methylation, single-cell analysis, and proteomics.
Builds sequencing and array platforms for research and clinical customers worldwide. Current lines include NovaSeq, NextSeq, MiSeq and iSeq sequencing families; Infinium arrays; library preparation and flow-cell consumables; and BaseSpace and DRAGEN informatics.
Links instruments to recurring consumables and software, so customer utilization of the installed base shapes demand for flow cells, reagents, kits, assays and service contracts. Newer workflows add methylation-aware DNA preparation, single-cell RNA analysis and NGS-read proteomics, including the SomaLogic portfolio.
Reports Core Illumina as one segment after spinning off GRAIL. Product availability varies by region and regulated-use status, and international access remains material. Instrument purchases in China still require government approval while the company remains on the Unreliable Entity List.
Company facts
Categories
Key statistics
Year to date +60.5% · Average volume (30d) 1.9M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Aug 5, 2026 | Deutsche Bank | Downgrade | Hold | ||
| Aug 3, 2026 | Canaccord Genuity | Reiterate | Hold | $190 | $205 |
| Jul 31, 2026 | RBC Capital | Reiterate | Outperform | $170 | $230 |
| Jul 31, 2026 | Bernstein | Reiterate | Market Perform | $185 | $215 |
| Jul 31, 2026 | Guggenheim | Reiterate | Buy | $200 | $226 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026Q2 FY26 | $1.23 | $1.31 | +6.5% | $1.13B | $1.16B | +2.5% | 0.00% |
| Apr 30, 2026Q1 FY26 | $1.05 | $1.15 | +9.5% | $1.07B | $1.09B | +1.7% | +7.13% |
| Feb 5, 2026Q4 FY25 | $1.24 | $1.35 | +8.9% | $1.12B | $1.16B | +3.6% | −10.40% |
| Oct 30, 2025Q3 FY25 | $1.17 | $1.34 | +14.5% | $1.07B | $1.08B | +1.6% | +24.78% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.04B | $1.06B | $1.08B | $1.16B | $1.09B | $1.16B | |
| Gross profit | $685.0M | $717.0M | $732.0M | $778.0M | $721.0M | $770.0M | |
| Operating income | $184.0M | $222.0M | $231.0M | $257.0M | $209.0M | $245.0M | |
| Net income | $131.0M | $235.0M | $150.0M | $334.0M | $134.0M | $207.0M | |
| Diluted EPS | $0.82 | $1.50 | $0.97 | $2.17 | $0.87 | $1.35 | |
| Gross margin | 65.8% | 67.8% | 67.6% | 67.1% | 66.1% | 66.4% | |
| Operating margin | 17.7% | 21.0% | 21.3% | 22.2% | 19.2% | 21.1% |
Fiscal years (4-quarter sums)FY21 $4.53B · FY22 $4.58B · FY23 $4.50B · FY24 $4.37B · FY25 $4.34B
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 28, 2026Cash & short-term investments $1.17B · Total debt $2.53B · Total assets $6.65B · Shareholders' equity $2.84B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 151.30M · Float 147.74M · 97.7% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 19.19M | 12.68% | 13F | Aug 7, 2026 |
| Capital World Investors | 15.43M | 10.20% | 13F | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 6.63M | 4.38% | 13F | Aug 13, 2026 |
| Vanguard Capital Management LLC | 6.59M | 4.35% | 13F | Aug 13, 2026 |
| State Street Corp | 6.51M | 4.30% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Keith A. Meister | director | −138,379 | $228.89 |
| Aug 26, 2026 | Keith A. Meister | director | −106,543 | $225.46 |
| Aug 25, 2026 | Keith A. Meister | director | −131,019 | $225.51 |
| Aug 21, 2026 | Keith A. Meister | director | −299,336 | $217.96 |
| Aug 20, 2026 | Keith A. Meister | director | −285,238 | $213.86 |
Peers
- Thermo Fisher Scientific
Broad overlap in sequencing, genotyping arrays, and proteomics
- PacBio
HiFi long reads contest complex-genome and multiomic sequencing workloads
- Onterris
Real-time native DNA and RNA sequencing from portable to high-throughput
- 10x Genomics
Single-cell and spatial workflows overlap expanding multiomics offerings
- Agilent Technologies
Array and NGS-preparation rival in genotyping, cancer, and methylation
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Illumina | $215.70 | +0.02% | $32.62B | 40.2 | 37.6 | 7.3 | +9.4% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| PacBio | $1.42 | +1.52% | $434.8M | — | — | 2.7 | −1.9% |
| Onterris | $17.04 | 0.00% | $615.8M | — | 82.7 | 0.8 | −20.4% |
| 10x Genomics | $61.54 | −0.01% | $7.81B | — | — | 12.7 | −12.7% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Median | 31.9 | 23.8 | 5.0 | −1.9% |